Annals of Emergency Medicine
Volume 49, Issue 2 , Pages 172-177, February 2007

Prescription Naloxone: A Novel Approach to Heroin Overdose Prevention

  • Karl A. Sporer, MD

      Affiliations

    • University of California, San Francisco, Department of Medicine, Section of Emergency Medicine, and the Treatment Research Center, the Urban Health Program, RTI International and the University of California, San Francisco, CA
    • Corresponding Author InformationAddress for correspondence: Karl Sporer, MD, Emergency Services, Room 1E21, San Francisco General Hospital, 1001 Potrero Ave, San Francisco, CA 94110; 415-206-5749, fax 415-206-5818
  • ,
  • Alex H. Kral, PhD

      Affiliations

    • Department of Family and Community Medicine, San Francisco, CA

Received 7 February 2006; received in revised form 30 March 2006 and 25 April 2006; accepted 23 May 2006. published online 14 July 2006.

The mortality and morbidity from heroin overdose have increased in the United States and internationally in the last decade. The lipid solubility allows the rapid deposition of heroin and its metabolites into the central nervous system and accounts for the “rush” experienced by users and for the toxicity. Risk factors for fatal and nonfatal heroin overdoses such as recent abstinence, decreased opiate tolerance, and polydrug use have been identified. Opiate substitution treatment such as methadone or buprenorphine is the only proven method of heroin overdose prevention. Death from a heroin overdose most commonly occurs 1 to 3 hours after injection at home in the company of other people. Numerous communities have taken advantage of this opportunity for treatment by implementing overdose prevention education to active heroin users, as well as prescribing naloxone for home use. Naloxone is a specific opiate antagonist without agonist properties or potential for abuse. It is inexpensive and nonscheduled and readily reverses the respiratory depression and sedation caused by heroin, as well as causing transient withdrawal symptoms. Program implementation considerations, legal ramifications, and research needs for prescription naloxone are discussed.

 

 Supervising editor: Richard D. Dart, MD, PhDFunding and support: The authors report this study did not receive any outside funding or support but discloses that KAS receives compensation for AED medical direction from American Health and Safety Training, Inc.Reprints not available from the authors.

PII: S0196-0644(06)00796-7

doi:10.1016/j.annemergmed.2006.05.025

Annals of Emergency Medicine
Volume 49, Issue 2 , Pages 172-177, February 2007